myocarditis and heart failure: diagnosis, prognosis and ... · treatment 24th annual heart failure...
TRANSCRIPT
Leslie T. Cooper, Jr., MD
Myocarditis and Heart Failure: Diagnosis, Prognosis and
Treatment
24th Annual Heart Failure 2020:
an Update on Therapy
August 1st, 2020
DISCLOSURE
Relevant Financial Relationship(s)
None
Off Label Usage
None
Outline
• Viral or Lymphocytic Myocarditis-
New definitions, diagnosis and management
• Giant Cell, Hypersensitivity, and Checkpoint
inhibitor myocarditis, Cardiac Sarcoidosis
Bozkurt, B et al Circulation 2016 Caforio, EHJ 2013
Myocarditis and Cardiomyopathy # Deaths and Death Rate /100,000
1990-2015
JACC, Nov 29th 2016
Lancet November 10th, 2018
1.37M myocarditis cases in 2019
343,000
Myocarditis Clinical Presentations
• Myopericarditis/MINOCA
• Sudden Death
• Acute Dilated Cardiomyopathy
• Chronic Dilated Cardiomyopathy
Acute Myocarditis EKG
CP1291921-1
I
II
III
aVR
aVL
aVF
V1
V2
V3
V4
V5
V6
QRS > 120ms, high degree heart block
Predict poor outcome
Mouse model of
CVB Myocarditis
Marholdt, H, etal. Circulation 2004
Epicardial-Mid Wall
Myocarditis: MRI and Histology
Fairweather, DL, Cooper, LT, et al
European Heart Journal, Volume 40, Issue Supplement_1, October 2019, ehz748.0565,
https://doi.org/10.1093/eurheartj/ehz748.0565
Detection Rate of Myocarditis
by MRI
2009 versus 2018 Lake Louise Criteria for Diagnosis of Acute Myocarditis
Leutkens, JA et al Radiology: Cardiothoracic Imaging 2019: 1(3)
Time Course of Native T1 and T2 Recovery in Acute
Myocarditis
Hinojar R et al. JACC Cardiovasc Imaging. 2015
Hinojar R J Cardiovasc Magn Reson. BioMed Central; 2014
Histologic “Dallas” Criteria
Aertz, et al Am J Pathol 1986
Sampling error, Variation in interpretation,
Low sensitivity, Lack of correlation with outcome
Baughman, K, Circulation 2006
Immuostains for the Diagnosis of Myocarditis
Nakayama et al EJHF 2017
CD3 CD68 CD163
Number of Inflammatory Cells Predicts Outcome in Myocarditis
Nakayama et al EJHF 2017
CD3-T cells CD68- Macrophages
Innsbruck and Maastricht
Inflammatory Cardiomyopathy Registry
Circ Heart Fail. 2018 ≥14 infiltrating inflammatory cells/mm2
AZA + Pred
↑ survival
• 374 patients with suspected myocarditis
• Chest pain 95%
• Age 35, 73% male; LVEF 62%
• Median FU 4.3 years
• Events: 26/374.
ITAMY Study Ten Center Italian Registry
2006-2013
Aquaro, et al JACC 2017
Anteroseptal Pattern on MRI Increased risk of MACE
Aquaro, et al JACC 2017
5 yr event probability 0.36 in AS group
• 670 patients with suspected myocarditis
• Chest pain 52% (LV dysfunction/ dyspnea 30%; Rhythm problems 18%)
• Age 47, 59% male; 13% QRS>120 ms
• All had MRI -294 with DGE
• Median FU 4.7 years
Brigham and Women’s Hospital MRI Case Series
2002-2015
Grani, C et al JACC 2017
DGE on CMR associated with greater risk of MACE
Grani, C et al JACC 2017
Annualized Risk of Death varies with LVEF and DGE
Grani, C et al JACC 2017
Ventricular Arrhythmias and Sudden Cardiac Death in Lymphocytic
Myocarditis
• Risk 0 after resolution of DGE
• Risk increased if DGE increases
Peretto. Et al, 25 (9) March 10th 2020
Cooper, LT JACC 25 (9) March 10th 2020
Kociol, R, Cooper, LT et al
Circulation February 2020
58 yo Woman admitted October 23, 2019
ECG Low QRS voltage due to myocardial edema An injury current with ST elevations in contiguous leads Pericarditis with PR segment changes may also be present Troponin is almost always elevated in 1st week* Echo May show normal LVEDD and left ventricular hypertrophy
Fulminant Myocarditis Sudden and severe inflammation resulting in myocyte necrosis,
edema, and cardiogenic shock.
Courtesy of Bill Edwards
Algorithm for the Evaluation of Suspected Myocarditis
in the Setting of Unexplained Acute DCM
Bozkurt, et al. Circulation, 2016
Unexplained Acute
Cardiomyopathy*
Required inotropic or mechanical circulatory support,
Mobitz type 2 second degree or higher heart block, sustained
or symptomatic ventricular tachycardia or failure to respond to
guideline based medical management within 1-2 weeks?
Yes-Endomyocardial Biopsy
COR I/LOE B
No-Cardiac MRI
COR 2B/LOE C
*Usually a dilated cardiomyopathy. Fulminant myocarditis may have normal end diastolic diameter with mildly thickened walls. Excluded ischemic, hemodynamic (valvular, hypertensive), metabolic, and toxic causes of cardiomyopathy as indicated clinically.
Survival in Fulminant Versus Nonfulminant Acute Myocarditis n=187
Enrico Ammirati, Circulation August 2017
Mason et al, NEJM. Aug 9th, 1995
No effect of Prednisone + AZA or CSA in LVEF or Survival
JACC, October 2017
Prognosis in Myocarditis Varies by Histology
0.0
0.2
0.4
0.6
0.8
1.0
0 1 2 3 4 5
Cooper, et al: N Engl J Med 1997 336:1860-66
Years
Pro
po
rtio
n s
urv
ivin
g
Giant-cell myocarditis
Lymphocytic myocarditis
P<0.0001
When to Suspect Giant Cell Myocarditis
• Rapidly Progressive course
• Failure to Respond to Usual Care
• Ventricular Tachycardia
• High-grade Heart Block
8 Of 28 (29%) screened subjects
in the GCM Trial had GCM
Cooper, LT. et al. Am Ht J 2008
Endomyocardial biopsy before and after OKT3, CSA, Steroid
immunosuppression
Sensitivity of EMB for GCM is 80-85%
Kandolin, R et al Circ HF 2013
GCM survival treated with Multidrug Immunosuppression
Eosinophilic Myocarditis
Brambatti, et al. JACC Nov 7th 2017
Clozapine: Example of Drug Hypersensitivity
• Myocarditis: Up to 1:1000
• 50/213 cases fatal
• 85% occur in first 2 months
of treatment
• Eosinophilia up to 66%
De Berardis, DD et al. Current Drug Safety 2012
Ben m’rad M, et al. Medicine 2009
• Prevalence of Myocarditis 1.14%
• CHB 3; CV shock 3; CV arrest 4 cases
• Overall 46% MACE rate over 102 days
• Median time from treatment 34 days
• Higher dose steroids associated with lower troponin and MACE rates
Checkpoint Inhibitor Myocarditis 8 Centers; n=35
Mahmood, SS JACC 2018
• Cardiotoxicity presents within 2 months with CHF or ventricular arrhythmias. MRI or biopsy
• Start methylprednisolone 1-2 mg/kg
• If deterioration, consider adding abatacept Annals of Oncology 2017
Brahmer, JR et al. J Clin Onc 2018
Insert image of page- Brahmer JR, et al. Management of
immune-related adverse events in patients treated
with immune checkpoint inhibitor therapy: American
Society of Clinical Oncology
clinical practice guideline. J Clin Oncol 2018;36:1714-
1768.
©2012 MFMER
| slide-37
48 year old woman with Complete Heart Block
Birnie, D et al 2014
Algorithm for the
Evaluation of Cardiac
Sarcoidosis
Sites of Cardiac Sarcoidosis at Autopsy
Kandolin 2015
Differential Diagnosis:
ARVC/ALVC
Myocarditis
Other Systemic Causes of
cardiac Inflammation:
eg.GPA
©2012 MFMER
| slide-40
SA
HLA
VLA
13N-NH3 defects and matched 18F-FDG uptake
associated with Cardiac Sarcoidosis
NH3 FDG
Cardiac PET and Prognosis in known or suspected CS
Blankstein, JACC 2014
Chareonthaitawee, P, J Nucl Cardiol. 2017
• Abnormal myocardial perfusion and metabolism had a four-fold increase in the annual rate of ventricular tachycardia or death compared to patients with normal imaging (n= 118)
• SNMMI Position Statement on The Role of PET/CT in Cardiac Sarcoidosis- August 2017
Baseline Following Infliximab
Courtesy of Jukka Lehtonen
FDG PET can follow
Response to Treatment
2020 Summary of Management of Acute/Fulminant Myocarditis
• All- GDMC and hemodynamic support- unloading if possible; avoid sports for 3-6 months.
• GCM- Immunosuppression including cyclosporine or tacrolimus; ATG or Campath, ICD if expected survival > 1 year.
• Checkpoint Inhibitor- Corticosteroids, Abatacept?
• Eosinophilic- Corticosteroids, Mepolizumab?
Randomized Clinical Trials 2020-2022
• IVIG for PVB19 positive Chronic DCM NCT 000659386- Maastrict
• Secukinumab (anti IL-17) for Acute myocarditis -Frankfurt
• Anakinra 100 mg SQ for CPI Myocarditis- until hospital discharge or a maximum of 14 days -Paris
• CASTT- Canadian Sarcoidosis Tx Trial (CHASM-CS; CHIR IRSC- Ottawa Heart)
• eMAP -electrogram biopsy(U Penn; Mayo)
Cardiac MRI and Biopsy with Sarcoidosis